SUMICHEM
Sumitomo Chemical India share price & financials
- Price
- ₹538.55
- Market cap
- ₹23.8k Cr
- Sector
- Chemicals
- Calls analysed
- 6
Sumitomo Chemi. Q4 FY26
What went well
- PAT grew by more than 7% year-to-year to INR543 crores, marking highest ever profitability performance in FY26.
- Gross profit margin stands at 42% and EBITDA margin at 20.7%, both record levels in company history.
- Top line grew by 3% while maintaining complete pricing integrity and negligible returns of goods.
What to watch
- FY26 was one of the most challenging years for the Indian agrochemical industry due to long and excess rainfall, geopolitical tensions, and global trade uncertainties.
- Export revenues declined 7% in Q4 and 1% for the full year due to shipment differences and softer demand conditions.
What Sumitomo Chemical India Limited does
Sumitomo Chemical India Limited (SCIL) manufactures and markets crop-protection chemicals — insecticides, herbicides, fungicides, plant growth regulators and metal-phosphide fumigants — along with animal nutrition and public-health/household pest-control products, sold under its own brand portfolio. It is the Indian flagship entity of Japan's Sumitomo Chemical Company, using in-house technical actives and R&D to formulate branded products for the domestic market as well as bulk/technical exports. Products reach farmers through a large network of direct distributors and depots, and the company also exports to a wide set of overseas markets across Africa, Asia, Europe and the Americas.
Segments
- Crop Protection
- Animal Nutrition Division (AND)
- Environmental Health Division (EHD)
- Manufacturing facilities
- 5 (Gajod, Vapi, Silvassa, Bhavnagar, Tarapur)
- In-house technical actives manufactured
- 14
- Brand portfolio
- 200+ brands
- Product SKUs
- 700+
- Direct distributor network
- 15,000+ distributors
- Depots
- 60
Guidance record · Q4 FY26
what the last two calls moved 12 tracked 3 delivered 2 missed 7 open- FY25 EBITDA Margin delivered said Q2 FY25 Promised: 18-20% for FY25 Q4 FY26: The promise pertains to FY25 and was achieved. Not discussed in the current quarter.
- Dahej Capex on track said Q2 FY24 Promised: Initial capex of ₹300 crores over the next 2-3 years. Q4 FY26: we have announced this capex of INR150 crores to be developed at our Dahej site. This is the first project coming at Dahej, and it is expected to be commercialized in next 2 years or so, and that continues on the track.
All 12 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 0.6%, net profit up 20.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 988 | 642 | 679 | 1,057 | 930 −6% | 568 −12% | 684 +1% | 1,063 +1% |
| EBITDA | 245 | 106 | 120 | 219 | 218 −11% | 99 −7% | 134 +12% | 233 +6% |
| Net profit | 193 | 87 | 100 | 178 | 178 −8% | 76 −13% | 111 +11% | 215 +21% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −16.9% 1Y
1Y: ₹573.25 on 10 Sept 2025 → ₹476.4. High ₹601.8 (19 Sept 2025), low ₹364.45 (30 Mar 2026).
How the price took the results
close before → close after
- Q4 FY26
- +1.2%
- 28 May
- Q2 FY26
- −1.1%
- 28 Oct
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue fell 2.7% a year over 3 years, FY23 to FY26. Operating margin widened to 20.7%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹3.5k Cr | ₹2.8k Cr | ₹3.1k Cr | ₹3.2k Cr |
| Operating profit | ₹668 Cr | ₹475 Cr | ₹632 Cr | ₹670 Cr |
| Operating margin | 19.0% | 16.7% | 20.1% | 20.7% |
| Interest | ₹4 Cr | ₹4 Cr | ₹6 Cr | ₹8 Cr |
| Depreciation | ₹51 Cr | ₹63 Cr | ₹66 Cr | ₹67 Cr |
| Net profit | ₹503 Cr | ₹370 Cr | ₹507 Cr | ₹543 Cr |
| Net margin | 14.3% | 13.0% | 16.1% | 16.8% |
| Cash from operations | ₹389 Cr | ₹757 Cr | ₹452 Cr | ₹446 Cr |
| Free cash flow | ₹270 Cr | ₹695 Cr | ₹423 Cr | ₹403 Cr |
| ROCE | 29.0% | 20.0% | 25.0% | 22.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹499 Cr | ₹499 Cr | ₹499 Cr | ₹499 Cr | ₹499 Cr | ₹499 Cr |
| Reserves | ₹1.0k Cr | ₹1.4k Cr | ₹1.9k Cr | ₹1.9k Cr | ₹2.7k Cr | ₹2.9k Cr |
| Borrowings | ₹33 Cr | ₹38 Cr | ₹34 Cr | ₹30 Cr | ₹49 Cr | ₹63 Cr |
| Other liabilities | ₹1.1k Cr | ₹1.0k Cr | ₹953 Cr | ₹841 Cr | ₹1.2k Cr | ₹1.0k Cr |
| Total liabilities | ₹2.7k Cr | ₹3.0k Cr | ₹3.4k Cr | ₹3.3k Cr | ₹4.4k Cr | ₹4.5k Cr |
| Fixed assets | ₹309 Cr | ₹390 Cr | ₹430 Cr | ₹563 Cr | ₹487 Cr | ₹577 Cr |
| Capital work in progress | ₹14 Cr | ₹35 Cr | ₹71 Cr | ₹23 Cr | ₹14 Cr | ₹20 Cr |
| Investments | ₹290 Cr | ₹356 Cr | ₹239 Cr | ₹346 Cr | ₹1.3k Cr | ₹1.2k Cr |
| Other assets | ₹2.1k Cr | ₹2.2k Cr | ₹2.6k Cr | ₹2.4k Cr | ₹2.6k Cr | ₹2.7k Cr |
| Total assets | ₹2.7k Cr | ₹3.0k Cr | ₹3.4k Cr | ₹3.3k Cr | ₹4.4k Cr | ₹4.5k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, DIIs added +1.18 pp while FIIs trimmed −0.63 pp. The shareholder count shrank 12% to 1,10,464.
- Promoters
- 75.0%
- FIIs
- 3.0%
- DIIs
- 9.3%
- Public
- 12.7%
Since Jun 2025
- DIIs +1.18 pp
- FIIs −0.63 pp
- Public −0.54 pp
How it drifted, 12 quarters
Over this window the public fell from 16.3% to 12.7% — −3.7 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 75.0%, FIIs 2.6%, DIIs 6.1%, Public 16.3%.Dec '23: Promoters 75.0%, FIIs 2.6%, DIIs 6.0%, Public 16.4%.Mar '24: Promoters 75.0%, FIIs 2.7%, DIIs 6.6%, Public 15.6%.Jun '24: Promoters 75.0%, FIIs 3.1%, DIIs 7.1%, Public 14.8%.Sep '24: Promoters 75.0%, FIIs 3.5%, DIIs 7.0%, Public 14.5%.Dec '24: Promoters 75.0%, FIIs 3.6%, DIIs 7.0%, Public 14.4%.Mar '25: Promoters 75.0%, FIIs 3.6%, DIIs 8.1%, Public 13.2%.Jun '25: Promoters 75.0%, FIIs 3.6%, DIIs 8.2%, Public 13.2%.Sep '25: Promoters 75.0%, FIIs 3.6%, DIIs 8.5%, Public 12.9%.Dec '25: Promoters 75.0%, FIIs 3.4%, DIIs 8.7%, Public 13.0%.Mar '26: Promoters 75.0%, FIIs 3.4%, DIIs 9.0%, Public 12.6%.Jun '26: Promoters 75.0%, FIIs 3.0%, DIIs 9.3%, Public 12.7%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Edelweiss Trusteeship Co Ltd Ac- Edelweiss Mf Ac- Edelweiss Mid Cap Fund Mutual fund newly disclosed 1.24% held
- Aditya Birla Sun Life Trustee Private Limited A/C - Aditya Birla Sun Life Large Cap Fund Mutual fund +0.26 pp 2.28% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Sumitomo Chemical India Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Sumitomo Chemical Co. Ltd. | 75.00% | unchanged |
| Aditya Birla Sun Life Trustee Private Limited A/C - Aditya Birla Sun Life Large Cap Fund Mutual fund | 2.28% | +0.26 pp |
| Edelweiss Trusteeship Co Ltd Ac- Edelweiss Mf Ac- Edelweiss Mid Cap Fund Mutual fund | 1.24% | newly disclosed |
| HSBC Mutual Fund - HSBC Small Cap Fund Mutual fund | 1.09% | unchanged |
| Sumitomo Pharma Trading (Suzhou) Co., Ltd. | 0.00% | unchanged |
| The Polyolefin Company (Singapore) Pte. Ltd. | 0.00% | unchanged |
| Botanical Resources Australia Pty Ltd. (BRA Group) | 0.00% | unchanged |
| Sumitomo Chemical Australia Pty. Ltd. | 0.00% | unchanged |
| McLaughlin Gormley King Company | 0.00% | unchanged |
| Mycorrhizal Applications, LLC | 0.00% | unchanged |
| Sumika Polymers North America LLC | 0.00% | unchanged |
| Sumitomo Chemical Advanced Technologies LLC | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in SUMICHEM
Filings to Aug 2026
0 new, 4 added, 1 trimmed, 0 sold out — net +0.04 L shares (+0.1%).
- Held by funds
- ₹200 Cr
- 6 schemes
- Biggest holder
- Nippon India Small Cap Fund
- ₹184 Cr · 0.2% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| Nippon India Small Cap Fund Nippon India Mutual Fund | ₹184 Cr | held | Jan '25 |
| Nippon India Nifty Smallcap 250 Index Fund Nippon India Mutual Fund | ₹10 Cr | +0.02 L | Sep '24 |
| SBI Nifty Smallcap 250 Index Fund SBI Mutual Fund | ₹5 Cr | +0.01 L | Sep '24 |
| Nippon India Nifty 500 Equal Weight Index Fund Nippon India Mutual Fund | ₹1 Cr | +0.00 L | Sep '24 |
| SBI Nifty 500 Index Fund SBI Mutual Fund | ₹0 Cr | −0.00 L | Sep '24 |
| SBI Nifty Small Cap 250 ETF SBI Mutual Fund | ₹0 Cr | +0.00 L | May '26 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
4 added, 1 trimmed — net +3,511 shares (+0.1%)
- Funds are sitting on
- +5%
- vs est. average cost
- Held by funds
- ₹200 Cr
- 6 schemes · ≈ 0.88% of the company
- Biggest holder
- Nippon India Small Cap Fund
- ₹184 Cr · 0.2% of that fund
- Longest holder
- Nippon India Nifty Smallcap 250 Index Fund
- 2y · since Sep '24
Shares held by these funds +647%
Aug '23 38.71 L shares Jul '26
What the price assumes
Growth trapTo justify its price of ₹476, this stock must grow earnings at 29% every year for 7 years. Our analysis caps realistic growth at ~3%. At that growth it is worth ₹120 — downside of 75%.
- Growth the price implies
- 29.0% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 2.6% a year
- net profit, FY23–FY26 · EPS 2.5%
- The gap
- 0.3 pp
- -75% downside if it only repeats history
All earnings calls (6)
Read the Q4 FY26 call →Learn to analyse Sumitomo Chemical India Limited
Guides on how to read this kind of business and the numbers that matter.